Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity and Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants.
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 05 Jan 2012 Results published in the Pediatric Infectious Disease Journal.
- 23 Oct 2008 Actual patient number (1009) added as reported by ClinicalTrials.gov.
- 01 Apr 2008 GlaxoSmithKline Biologicals reported as trial affiliate by ClinicalTrials.gov.